• 1
    Loftus CG, Loftus EV, Harmsen WS, et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000. Inflamm Bowel Dis 2007; 13: 25461.
  • 2
    Kornbluth A, Sachar DB, The Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010; 105: 50123.
  • 3
    Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001; 96: 292933.
    Direct Link:
  • 4
    Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 2003; 114: 3943.
  • 5
    Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18: 1918.
  • 6
    Cervený P, Bortlík M, Kubena A, Vlcek J, Lakatos PL, Lukás M. Nonadherence in inflammatory bowel disease: results of factor analysis. Inflamm Bowel Dis 2007; 13: 12449.
  • 7
    Kane S, Shaya F. Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci 2008; 53: 10204.
  • 8
    Sewitch MJ, Abrahamowicz M, Barkun A, et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol 2003; 98: 153544.
    Direct Link:
  • 9
    Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005; 100: 134553.
    Direct Link:
  • 10
    Moody GA, Jayanthi V, Probert CS, Mac Kay H, Mayberry JF. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996; 8: 117983.
  • 11
    Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 48797.
  • 12
    Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health 2008; 11: 447.
  • 13
    Steiner JF, Koepsell TD, Fihn SD, Inui TS. A general method of compliance assessment using centralized pharmacy records. Description and validation. Med Care 1988; 26: 81423.
  • 14
    Trindade AJ, Ehrlich A, Kornbluth A, Ullman TA. Are your patients taking their medicine? Validation of a new adherence scale in patients with inflammatory bowel disease and comparison with physician perception of adherence. Inflamm Bowel Dis 2011; 17: 599604.
  • 15
    Long MD, Kappelman MD, Martin CF, et al. Development of an internet-based cohort of patients with inflammatory bowel diseases (CCFA Partners): methodology and initial results. Inflamm Bowel Dis 2012; doi: 10.1002/ibd.22895 [Epub ahead of print].
  • 16
    Ford AC, Khan KJ, Sandborn WJ, Kane SV, Moayyedi P. Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 20707.
  • 17
    Krousel-Wood M, Islam T, Webber LS, Re RN, Morisky DE, Muntner P. New medication adherence scale versus pharmacy fill rates in seniors with hypertension. Am J Manag Care 2009; 15: 5966.
  • 18
    Steiner JF, Ho PM, Beaty BL, et al. Sociodemographic and clinical characteristics are not clinically useful predictors of refill adherence in patients with hypertension. Circ Cardiovasc Qual Outcomes 2009; 2: 4517.
  • 19
    Royston P. Explained variation for survival models. The Stata Journal 2006; 6: 8396.
  • 20
    Gillespie BWG. Use of generalized R-squared in Cox regression. In: American Public Health Association (APHA) 134th Meeting and Exposition. Boston, MA: APHA, 2006. Available at:
  • 21
    Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 2009; 44: 43140.
  • 22
    Louis E, Belaiche J, Reenaers C. Do clinical factors help to predict disease course in inflammatory bowel disease? World J Gastroenterol 2010; 16: 26003.
  • 23
    Yu S, Burge RT, Foster SA, Gelwicks S, Meadows ES. The impact of teriparatide adherence and persistence on fracture outcomes. Osteoporos Int 2012; 23: 110313.
  • 24
    Sajatovic M, Valenstein M, Blow F, Ganoczy D, Ignacio R. Treatment adherence with lithium and anticonvulsant medications among patients with bipolar disorder. Psychiatr Serv 2007; 58: 85563.
  • 25
    Holtmann MH, Krummenauer F, Claas C, et al. Significant differences between Crohn's disease and ulcerative colitis regarding the impact of body mass index and initial disease activity on responsiveness to azathioprine: results from a European multicenter study in 1,176 patients. Dig Dis Sci 2010; 55: 106678.
  • 26
    Siegel CA. Accidentally ASCENDing into comparative effective research for inflammatory bowel disease. Gastroenterology 2009; 137: 18802.
  • 27
    Trindade AJ, Morisky DE, Ehrlich AC, Tinsley A, Ullman TA. Current practice and perception of screening for medication adherence in inflammatory bowel disease. J Clin Gastroenterol 2011; 45: 87882.
  • 28
    Dezii CM. Medication noncompliance: what is the problem? Manag Care 2000; 9(Suppl.): 712.
  • 29
    Tindall WN, Boltri JM, Wilhelm SM. Mild-to-moderate ulcerative colitis: your role in patient compliance and health care costs. J Manag Care Pharm 2007; 13(Suppl. A): S212.
  • 30
    Kane S. Medication adherence and the physician-patient relationship. Am J Gastroenterol 2002; 97: 1853.
    Direct Link:
  • 31
    Kane S, Huo D, Magnanti K. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol 2003; 1: 1703.
  • 32
    Prantera C, Viscido A, Biancone L, Francavilla A, Giglio L, Campieri M. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm Bowel Dis 2005; 11: 4217.
  • 33
    Safdi MA. Current Treatment Landscape of Mild-to-Moderate Ulcerative Colitis. J Gastroenterol Hepatol Feb, 2010; 6(Suppl. 4): 56.
  • 34
    López San Román A, Bermejo F, Carrera E, Pérez-Abad M, Boixeda D. Adherence to treatment in inflammatory bowel disease. Rev Esp Enferm Dig 2005; 97: 24957.
  • 35
    Kane SV. Overcoming adherence issues in ulcerative colitis. Gastroenterol Hepatol (N Y) 2007; 3: 7959.
  • 36
    Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JH. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis 2008; 14: 16606.
  • 37
    Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997; 50: 10516.
  • 38
    Kramer JR, Davila JA, Miller ED, Richardson P, Giordano TP, El-Serag HB. The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases. Aliment Pharmacol Ther 2008; 27: 27482.
  • 39
    Anaya DA, Becker NS, Richardson P, Abraham NS. Use of administrative data to identify colorectal liver metastasis. J Surg Res 2012; 176: 1416.
  • 40
    Thirumurthi S, Chowdhury R, Richardson P, Abraham NS. Validation of ICD-9-CM diagnostic codes for inflammatory bowel disease among veterans. Dig Dis Sci 2010; 55: 25928.
  • 41
    Hanratty R, Estacio RO, Dickinson LM, et al. Testing electronic algorithms to create disease registries in a safety net system. J Health Care Poor Underserved 2008; 19: 45265.
  • 42
    Cooke CR, Joo MJ, Anderson SM, et al. The validity of using ICD-9 codes and pharmacy records to identify patients with chronic obstructive pulmonary disease. BMC Health Serv Res 2011; 11: 37.